Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $220
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $253 to $220.
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $253 to $220.